Table 2.
Changes in VAS scores and pain intensity. (PPS, N = 128).
| Variable | Group | 4 w | 8 w | 12 w | Follow-up period |
|---|---|---|---|---|---|
| CXDT-HFG group (n = 86) | 4.96 ± 2.01 | 4.02 ± 2.33 | 2.39 ± 2.41 | 1.66 ± 2.15 | |
| VAS scores§ | Placebo group (n = 42) | 4.90 ± 2.09 | 4.12 ± 2.41 | 3.21 ± 2.45 | 2.92 ± 2.51 |
| P* values | 0.893 | 0.679 | 0.060 | 0.005‡ | |
|
| |||||
| CXDT-HFG group (n = 86) | |||||
| No pain, n (%) | 7 (8.14%) | 15 (17.44%) | 37 (43.02%) | 49 (56.98%) | |
| Mild, n (%) | 15 (17.44%) | 24 (27.91%) | 27 (31.40%) | 23 (26.74%) | |
| Moderate, n (%) | 57 (66.28%) | 43 (50.00%) | 21 (24.42%) | 13 (15.12%) | |
| Severe, n (%) | 7 (8.14%) | 4 (4.65%) | 1 (1.16%) | 1 (1.16%) | |
| Pain intensity# | Placebo group (n = 42) | ||||
| No pain, n (%) | 4 (9.52%) | 8 (19.05%) | 12 (28.57%) | 16 (38.10%) | |
| Mild, n (%) | 9 (21.43%) | 13 (30.95%) | 11 (26.19%) | 10 (23.81%) | |
| Moderate, n (%) | 25 (59.52%) | 19 (45.24%) | 19 (45.24%) | 16 (38.10%) | |
| Severe, n (%) | 4 (9.52%) | 2 (4.76%) | 0 (0.00%) | 0 (0.00%) | |
| P* values | 0.684 | 0.673 | 0.037‡ | 0.013‡ | |
W: weeks. Significant difference, P < 0.05. Data presented as mean ± SD, number (percentage).
*P for comparison with control group.
# P values based on Chi-square test.
§ P values based on repeated measures.
‡ P < 0.05. Statistical differences for comparison between groups.